RhoA controls myoblast survival by inducing the phosphatidylinositol 3-kinase-Akt signaling pathway  by Reuveny, Mickol et al.
FEBS 28515 FEBS Letters 569 (2004) 129–134RhoA controls myoblast survival by inducing the phosphatidylinositol
3-kinase-Akt signaling pathwayMickol Reuveny, Hanna Heller, Eyal Bengal*
Department of Biochemistry, Faculty of Medicine, Rappaport Institute for Research in the Medical Sciences,
Technion-Israel Institute of Technology, P.O. Box 9649, Haifa 31096, Israel
Received 10 May 2004; accepted 25 May 2004
Available online 7 June 2004
Edited by Jesus AvilaAbstract The small GTPase RhoA regulates the expression of
the myogenic transcription factor, MyoD, and the transcription
of muscle-speciﬁc genes. We report that RhoA also aﬀects the
survival of diﬀerentiating myoblasts. Two signaling pathways,
extracellular signal-regulated kinase (ERK) and phosphatidyl-
inositol 3-kinase (PI3-K)-Akt, are involved in myoblast survival.
Here, we show that inhibition of RhoA prevents the phosphor-
ylation of Akt, but does not aﬀect the phosphorylation of ERK.
Constitutive expression of an active form of Akt prevents
apoptosis in myoblasts treated with the Rho inhibitor C3-
transferase. These results indicate that RhoA functions to
prevent myoblast death by inducing the PI3-K-Akt pathway.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The Rho GTPases aﬀect various cellular functions [1] in-
cluding cytoskeleton rearrangement, cell motility, cell growth
and cytokinesis [2]. This group of GTPases works as molecular
switches that transmit intracellular signals from growth factors
or G protein coupled receptors.
The Rho GTPases have been implicated in diﬀerent aspects
of the diﬀerentiation of myoblasts. Rac1 and Cdc42 members
of the family induce myoblast proliferation and inhibit the
expression of muscle-speciﬁc genes [3,4], while RhoA induces
diﬀerentiation [5]. RhoA is directly involved in muscle-speciﬁc
transcription [3,5]. The activity of RhoA is required for the
expression of MyoD, a key regulator of skeletal muscle dif-
ferentiation, but not of another family member, Myf5 [5]. The
transcriptional regulator, serum response factor (SRF), medi-
ates the eﬀect of RhoA on MyoD transcription. Recently, the
DNA binding site for SRF was identiﬁed at one of the regu-
latory regions of the MyoD gene [6]. Thus, a signaling pathway* Corresponding author. Fax: +972-4-8553-299.
E-mail address: bengal@tx.technion.ac.il (E. Bengal).
Abbreviations: ERK, extracellular signal-regulated kinase; PI3-K,
phosphatidylinositol 3-kinase; GM, growth medium; DM, diﬀerenti-
ation medium; MHC, myosin heavy chain; DN, dominant negative;
Act, activated; MD:ER, MyoD-estrogen receptor; ROK, Rho kinase
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doi:10.1016/j.febslet.2004.05.035emerges that links RhoA via SRF to the expression of MyoD,
and is probably the reason for the positive eﬀect of RhoA on
muscle-speciﬁc gene expression.
A recent study strengthened the concept of Rho involvement
in skeletal muscle speciﬁcation [7]. Cells derived from embryos
lacking p190-BRhoGAP and exhibiting excessive Rho activity
were defective for adipogenesis, but underwent myogenesis
under the proper growth conditions.
In the present work, we investigated other aspects of Rho
involvement in muscle diﬀerentiation than the already known
eﬀect on muscle transcription. Our study shows that RhoA
activity which is induced during myoblast diﬀerentiation af-
fects myotube-structure and prevents the programmed cell
death (PCD) of myoblasts. Our study suggests that the known
survival pathway, phosphatidylinositol 3-kinase (PI3-K)-Akt
[8,9], is found downstream to RhoA.2. Materials and methods
2.1. Materials
RhoA monoclonal antibody (SC-418), MyoD polyclonal antibody
(SC-760), and Myogenin monoclonal antibody (SC-12732) were from
Santa Cruz Biotechnology. A monoclonal antibody to MyoD (5.8A)
was from Novocastra. A monoclonal antibody to myosin heavy chain
(MHC) (MF-20) was a gift from Dr. S. Tapscott. A monoclonal an-
tibody to a tubulin was from Sigma. Phospho-Akt polyclonal antibody
(#9270), Akt polyclonal antibody (#9272), p44/42 MAP kinase (ex-
tracellular signal-regulated kinase, ERK) polyclonal antibody (#9102)
and phospho-p44/42 MAP kinase (phospho-ERK) polyclonal anti-
body (#9102) were from Cell signaling. An antibody to active
caspase 3 was from R&D systems.2.2. Plasmids
pCEFL AU5 RhoAQ63L and pCEFL AU5 RhoAN19 and pCEFL
AU5 RhoA wt were a generous gift from Dr. JS Gutkind (NIH). These
pCEFL-AU5 expression vectors were described in an article by Ter-
amoto and colleagues [10]. A BamH1–EcoR1 fragments encoding for
the ORF of RhoA N19 and a HindIII–EcoRI fragment encoding for
the ORF of the RhoAQ63L were cloned into the pBABE-Puro ret-
roviral vector. Myr-Akt-HA fragment [11] was cloned into the retro-
viral vector pLNCX v.2 [12] to generate pCL-Myr-Akt-HA-NCX.
Expression vectors of HA-Akt mutants (CMV5) were described before
[13]. pBABE-MyoD:ER-puro was obtained from S. Tapscott
(FHCRC, Seattle). Construction of the bacterial expression vector of
C3-Tat was described before [14].2.3. Cell culture
C2 cells were a gift from Dr. David Yaﬀe [15]. Cell lines were
maintained in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)blished by Elsevier B.V. All rights reserved.
Fig. 1. The activity of endogenous RhoA increases in diﬀerentiating
C2 cells. The amount of Rho-GTP (active Rho) was analyzed as
described in Section 2 using extracts that were prepared from C2 cells
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mycin (Growth Medium, GM). To induce diﬀerentiation, we used
DMEM supplemented with 10 lg of insulin per ml and 10 lg of
transferrin per ml (Diﬀerentiation medium, DM).
2.4. Preparation of C3 transferase-Tat
A bacterially expressed chimera protein of Clostridium botulinum
C3 fused to the transduction domain of the HIV Tat protein was
produced in Escherichia coli and puriﬁed as previously described [14].
The C3 Tat protein was added directly to DM at a concentration of
50 lg/ml. The medium was replaced every 24 h by medium con-
taining fresh inhibitor.
2.5. Generation of stable C2 clones
C2 cells were infected with replication-defective viruses carrying
pBABE-Puro, pBABE-Puro RhoAQ63L, pBABE-Puro RhoAN19,
pCL-Myr-Akt-HA-NCX and pBABE-MyoD:ER-puro vectors. Ret-
roviruses were generated as described [12]. Infected cells were selected
with Puromycin (3 lg/ml) or Neomycin (1 mg/ml).grown in DM for diﬀerent periods of time as indicated. One ﬁfth of
the protein extract used to isolate Rho-GTP was used to detect total
Rho. Rho-GTP, total-RhoA and MHC were detected by Western
blotting.2.6. Transfection of 293T cells, immunoprecipitations and kinase assay
Calcium phosphate method was used to transfect cells. Cells were
lysed and whole cell extracts were collected. Tagged proteins were
immunoprecipitated using an anti-HA antibody (Babco inc.) Kinase
activity of Akt was analyzed as described before using the peptide
GRPRTSSFAEG as a substrate [16].2.7. Immunohistochemical staining
Cells were ﬁxed and immunostained as described [17]. The primary
antibodies used were anti active caspase 3 and anti MHC. Nuclei were
stained with 40,6-diamidino-2-phenylindole (DAPI).
2.8. GTP loading of RhoA
Speciﬁc isolation of RhoA-GTP was performed as described previ-
ously [18].2.9. Western blot analysis
Cells were lysed and whole cell extracts were collected as described
[17]. Equal amounts of extracted proteins (40 lg) were loaded and
separated over 12.5% SDS–PAGE and transferred to nitrocellulose
membranes. Immunoblotting was conducted as described [17]. Pro-
teins were visualized using the enhanced chemiluminescence kit of
Pierce Inc.3. Results and discussion
3.1. The activity of RhoA is induced during growth of C2 cells in
diﬀerentiation medium
For studying the involvement of RhoA in the diﬀerentiation
of myoblasts, the endogenous activity of RhoA was deter-
mined in a C2 myoblast cell line. In its active form, Rho is
bound to GTP and interacts with its eﬀector proteins. Protein
extracts from C2 cells grown for diﬀerent time periods in DM
were incubated with a bacterially puriﬁed chimera eﬀector,
GST-Rhotekin. Levels of activated RhoA were determined by
their interaction with GST-Rhotekin and identiﬁed by Western
blotting (Fig. 1). The amount of RhoA-GTP was low in di-
viding myoblasts and was higher in cells grown in DM for
diﬀerent periods of time.
3.2. RhoA aﬀects the structure of myotubes
For understanding RhoA function during myoblast diﬀer-
entiation, C2 cells were infected with retroviruses encoding for
a constitutively active form of RhoA (RhoA Q63L) or a
dominant negative (DN) form of the protein (RhoA N19).
Expression levels of exogenous Rho mutant proteins in thesecells were up to three fold higher than endogenous RhoA
(Fig. 2A, compare lanes 1–4 to 4–8 and 9–12).
RhoA was demonstrated before to aﬀect the expression of
MyoD [5]. We analyzed the expression of several myogenic
markers during the growth of these cell lines in DM
(Fig. 2A). Indeed, MyoD protein levels were signiﬁcantly
reduced at all times in the DN-RhoA expressing cells relative
to the control C2 cells. The same cells expressed low levels of
the early marker, myogenin, and undetectable levels of the
late marker, MHC. The cells expressing the active form of
RhoA expressed high levels of all myogenic markers, how-
ever, the expression was delayed relative to the control cells
(Fig. 2A). The eﬀect of RhoA mutants on myogenic diﬀer-
entiation was analyzed also by immunostaining of myotubes
with an antibody to MHC (Fig. 2B). Myotubes were detected
in the control cells, but not in the cells expressing DN-RhoA.
Myotubes were also detected in the cells expressing Act-
RhoA, but their structure was very diﬀerent from that of the
control cells. These myotubes were much thicker and shorter
(Fig. 2B, compare C2-puro to Act-RhoA). The average
number of nuclei per myotube was similar in these two cell
lines (data not shown). Together, these data suggest that
besides its eﬀect on the expression of myogenic markers,
RhoA also aﬀects the structure of myotubes.
3.3. RhoA does not aﬀect the exit of myoblasts from the cell
cycle
Since the withdrawal of myoblasts from the cell cycle is di-
rectly linked to their diﬀerentiation, we compared the with-
drawal of the diﬀerent cell lines from the cell cycle. By several
criteria: the expression of cyclin D1, phosphorylation state of
pRb, and BrdU staining of nuclei, RhoA expression did not
signiﬁcantly alter the withdrawal of myoblasts from the cell
cycle (data not shown).
Another cell cycle regulator, the cyclin-dependent kinase
inhibitor p21waf1 normally induced during the withdrawal of
myoblasts from the cell cycle, was aﬀected by the expression of
RhoA mutants (Fig. 3A) [19]. The levels of p21waf1 in the pa-
rental cell line and in the cells expressing activated Rho were
induced during diﬀerentiation, though induction of p21waf1
Fig. 2. RhoA aﬀects both the expression of myogenic markers and the structure of myotubes. (A) C2 cells expressing the diﬀerent forms of RhoA
and a control vector (Puro) were grown in GM to 80% conﬂuence and then in DM for the indicated time periods. Proteins were extracted and
separated over SDS–PAGE and analyzed by Western blotting. The blot was reacted with diﬀerent muscle-speciﬁc antibodies as indicated and
with anti a tubulin antibody. The levels of RhoA were determined in a separate experiment. The amount of a tubulin served as a control for the
loading of proteins in each lane. (B) C2 cells expressing the diﬀerent forms of RhoA and the control cells were grown in DM for 48 h. Cells were
ﬁxed and myotubes were identiﬁed by immunostaining with MHC antibody (left panel). Nuclei of the same microscopic ﬁelds were stained with
DAPI (right panel).
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9–12). The levels of p21waf1 were low and did not change
during the growth of cells expressing DN RhoA in DM (lanes
5–8). The low levels of p21waf1 in these cells could aﬀect their
survival state. It is well documented that the resistance of
myoblasts to apoptosis is correlated to the expression of
p21waf1 [19]. Therefore, we further investigated the possible
link between Rho and the survival of myoblasts.3.4. Inhibition of RhoA causes apoptotic cell death of myoblasts
To ﬁnd out whether the absence of Rho activity could induce
cell death, we added C3 transferase to the medium of C2 myo-
blasts (see Section 2). The exoenzyme C3 transferase inactivates
Rhoproteins byADP-ribosylation but notCDC42andRac [20].
Following 48 h of growth in DM, C2 cell lines and C2 cells
treated with C3-transferase were immunostained with an an-
tibody that recognized the active form of caspase 3 (Fig. 3B).
Fig. 3. Inhibition of RhoA causes apoptosis of diﬀerentiating myoblasts. (A) C2 cells expressing the diﬀerent forms of RhoA were grown as described
in Fig. 2. Proteins were extracted and separated over SDS–PAGE and analyzed by Western blotting. The blot was reacted with antibodies to p21 and
a tubulin. (B) Conﬂuent C2 cells expressing DN Rho and conﬂuent parental C2 cells grown in the absence or presence of C3-transferase (50 lg/ml)
were left in DM for 48 h. Upper panel: Apoptotic cells were detected by immunostaining with an antibody recognizing the active processed form of
caspase 3. Nuclei of the same ﬁelds were stained with DAPI. Lower panel: Quantiﬁcation of the caspase 3 experiment. For each experiment, about
600 nuclei were counted. The percentage of apoptotic cells was calculated by dividing the number of caspase 3-stained cells by the total number of
nuclei. Values are means from three independent experiments. Error bars represent standard errors.
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active caspase 3. More than 30% of the Rho DN expressing
cells and 70% of the cells treated with C3 transferase stained
positively for active caspase 3. Similar results were obtained
using a TUNEL assay (data not shown). Therefore, these data
suggest that inhibition of Rho activity results in a substantial
percentage of cells undergoing apoptosis.
3.5. Phosphorylation of Akt is decreased while the
phosphorylation of ERK is unaﬀected in C2 cells treated
with Rho inhibitor
Two signaling pathways, ERK and PI3-K-Akt, are involved
in the expression of p21waf1 and promote myoblast survival
[9,21]. To ﬁnd out whether these pathways are found down-
stream to RhoA, C2 cells were grown in DM in the presence or
absence of C3-transferase, and the phosphorylation status ofAkt and ERK was investigated (Fig. 4A). Phosphorylation of
Akt and ERK is transiently induced during the diﬀerentiation
of C2 cells (Fig. 4A, lanes 1–4) [17,22]. Treatment of C2 cells
with C3 transferase decreased the phosphorylation of Akt but
not of ERK during diﬀerentiation (Fig. 4A, compare lanes 2–4
to 5–7). This result indicates that Akt is downstream relative to
RhoA, and therefore may explain the involvement of RhoA in
the expression of p21waf1 and the survival of myoblasts [19]. To
further explore this possibility, we transfected RhoA mutants
into 293T cells and analyzed the kinase activity of Akt in ex-
tracts from these cells (Fig. 4B). Wild type and activated RhoA
increased the kinase activity of Akt, while treatment of cells
with LY294002 blocked its activity. Therefore, RhoA aﬀects
PI3-K and consequently the kinase activity of Akt. Rho pro-
teins were previously shown to activate PI3-K and Akt pro-
teins [23,24], yet the mechanism of activation remains
Fig. 5. Myr-Akt can restore the expression of p21waf1 and prevents
programmed-cell death in C2 cells treated with C3-transferase. C2
cells, C2 cells expressing myristoylated Akt and C2 cells expressing
MyoD-ER proteins were grown in GM to 80% conﬂuence and then for
additional 48 h in DM in the presence or absence of C3-transferase.
(A) Proteins were extracted and separated over SDS–PAGE and an-
alyzed by Western blotting. The blot was reacted with antibodies to
p21waf1, myogenin, phosphorylated Akt (Ser 473; pAkt) and total Akt.
(B) Cells were grown as described above and then ﬁxed. Apoptotic cells
were detected by immunostaining with an antibody recognizing the
active processed form of caspase 3. For each experiment, about 600
nuclei in at least 10 microscopic ﬁelds were counted. The percentage of
apoptotic cells was calculated by dividing the number of caspase 3-
stained cells by the total number of nuclei. Error bars represent stan-
dard errors.
Fig. 4. Inhibition of Rho prevents the phosphorylation of Akt in dif-
ferentiating myoblasts. (A) C2 cells were grown in GM and then in
DM in the presence or absence of C3 transferase. At the indicated time
points in DM, cells were lysed and proteins were extracted, separated
over SDS–PAGE and analyzed by Western blotting. Membrane was
reacted with antibodies to phosphorylated Akt (Ser 473; pAkt), total
Akt, phosphorylated ERK (Thr 202/Tyr 204; pERK), total ERK and a
tubulin. (B) 293T cells were transfected with expression vectors coding
for diﬀerent RhoA and Akt proteins. 48 h later, cells were lysed and
proteins were extracted. HA-tagged Akt proteins were immunopre-
cipitated and their kinase activity was measured as described [16]. The
data are presented as fold activation relative to wt HA-Akt. The rel-
ative amount of immunoprecipitated Akt proteins was analyzed by
Western blot. HA-Akt DD-constitutively active Akt; HA-Akt AA-
kinase dead Akt.
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tween subunits of PI3-K and small GTPases [25–28]. We ex-
amined this possibility, and our preliminary results indicate
association of the catalytic subunit of PI3-K, p110 with RhoA
in transfected cells (data not shown).
3.6. Expression of activated-Akt rescues C2 cells from apoptosis
induced by RhoA inhibition
If Akt is indeed downstream to RhoA, one would expect
that the expression of constitutively active Akt can reverse the
eﬀects of Rho inhibition in diﬀerentiating C2 cells. A C2 cell
line expressing myristoylated-Akt, a constitutively active
membrane-bound Akt, was isolated. The myristoylated-Aktwas highly phosphorylated also when this cell line was grown
in the presence of C3-transferase, suggesting that the protein
was constitutively active (Fig. 5A, lanes 3, 4). In contrast to the
control C2 cells, growth of this cell line in the presence of C3-
transferase did not decrease the levels of p21waf1 as compared
to cells grown in its absence (Fig. 5A, compare lanes 1, 2 to 3,
4). Nevertheless, the expression of myristoylated Akt did not
restore the expression of myogenin that was signiﬁcantly
inhibited by C3 transferase (Fig. 5A, lanes 1–4). Since the
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expression (Fig. 2A) [5], we further studied the ability of forced
expression of MyoD to rescue muscle diﬀerentiation. For that,
an inducible MyoD protein (MD:ER; a chimera protein of
MyoD and the hormone binding domain of estrogen receptor)
was constitutively expressed in C2 cells. The active MD:ER
protein was able to rescue the expression of both p21waf1 and
the myogenin proteins in the presence of C3 transferase. Still,
the MD:ER protein did not rescue the phosphorylation of Akt
that was almost undetectable in the presence of C3 transferase
(Fig. 5A, lane 6). To further investigate whether activated Akt
or forced expression of MyoD could rescue the substantial
apoptosis occurring in myoblasts grown in the presence of C3
transferase, the diﬀerent cell lines were immunostained with an
antibody that recognized the active form of caspase 3 follow-
ing their growth in DM (Fig. 5B). Whereas C3 transferase
induced a sharp increase from about 15 to 70% in parental C2
cells positively stained for active caspase 3, it barely changed
the relative amount of stained-cells expressing myristoylated
Akt or MD:ER.
From this set of experiments we can conclude that: (a) Ac-
tive Akt can rescue apoptosis that is induced by lack of Rho
activity, but not the expression of myogenin. (b) MD:ER
protein can rescue both the expression of myogenin and ap-
optosis independently of the phosphorylation state of Akt.
Overall, our results suggest additional functions for RhoA in
myogenesis besides those known so far. One function is to
promote the survival of myoblasts via the PI3-kinase-Akt
pathway. This pathway prevents myoblast apoptosis, but does
not aﬀect muscle transcription (Fig. 5). A second fucntion is to
aﬀect the structure of myotubes (Fig. 1). Experiments not
presented here suggest that this function is mediated by Rho
kinase (ROK). However, ROK does not function as an eﬀector
of RhoA in the activation of PI3-K-Akt. A third, previously
described function is the transcriptional activation of MyoD
[5]. As a major regulator of MyoD, of the PI3-kinase pathway
and of the structure of myotubes, RhoA proves to be a key
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